Bruker completed the investment in NovAliX.

Bruker, a manufacturer of scientific instruments and diagnostic tests, completed the investment in NovAliX, a drug discovery focused CRO. Financial terms were not disclosed. “This partnership with Bruker will fortify our leadership in biophysics and drug discovery. Leveraging Bruker’s state-of-the-art analytical technologies and expertise, we can offer advanced biophysical methods to our clients. This collaboration promises to drive significant advancements in drug discovery, leading to new and effective treatments for patients globally,” Stephan Jenn, NovAliX President and Co-founder.